Eric Venker Sells 14,229 Shares of Immunovant (NASDAQ:IMVT) Stock

Immunovant, Inc. (NASDAQ:IMVT) CEO Eric Venker sold 14,229 shares of the business’s stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $24.10, for a total transaction of $342,918.90. Following the transaction, the chief executive officer directly owned 19,561 shares in the company, valued at $471,420.10. This trade represents a 42.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Immunovant Price Performance

Shares of Immunovant stock opened at $24.50 on Friday. Immunovant, Inc. has a fifty-two week low of $12.72 and a fifty-two week high of $29.25. The firm has a fifty day moving average price of $25.75 and a two-hundred day moving average price of $23.52. The company has a market cap of $4.99 billion, a PE ratio of -9.11 and a beta of 0.67.

Immunovant (NASDAQ:IMVT) last posted its quarterly earnings data on Friday, February 6th. The company reported ($0.61) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.11. During the same quarter in the prior year, the company posted ($0.76) EPS. Analysts expect that Immunovant, Inc. will post -2.69 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Immunovant

A number of hedge funds have recently modified their holdings of IMVT. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Immunovant by 8.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,971 shares of the company’s stock valued at $708,000 after buying an additional 3,348 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in Immunovant by 48.6% during the first quarter. Goldman Sachs Group Inc. now owns 1,007,700 shares of the company’s stock worth $17,222,000 after acquiring an additional 329,354 shares in the last quarter. Strs Ohio bought a new position in shares of Immunovant during the first quarter valued at $27,000. Creative Planning lifted its holdings in shares of Immunovant by 21.2% during the second quarter. Creative Planning now owns 35,368 shares of the company’s stock valued at $566,000 after acquiring an additional 6,175 shares during the period. Finally, Legal & General Group Plc boosted its stake in shares of Immunovant by 6.9% in the 2nd quarter. Legal & General Group Plc now owns 77,296 shares of the company’s stock valued at $1,237,000 after purchasing an additional 5,010 shares in the last quarter. 47.08% of the stock is owned by institutional investors and hedge funds.

Key Immunovant News

Here are the key news stories impacting Immunovant this week:

• Positive Sentiment: Management highlights brepocitinib program expansion as a strategic response, signaling a shift of R&D and commercial focus toward the oral JAK/TYK2 asset that could partially offset the batoclimab setback; this gives investors a tangible alternative program to watch for future value creation. Immunovant Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript
• Neutral Sentiment: Company released additional corporate materials/slideshow discussing the pipeline and Phase 3 update; these materials provide management context but don’t replace the clinical outcomes that move valuation. Monitor upcoming investor calls or detailed data disclosures for clarification. Slideshow: Brepocitinib and Batoclimab Phase III Data Update
• Negative Sentiment: Batoclimab failed to meet primary endpoints in Phase 3 TED trials — multiple outlets report the late‑stage miss and its immediate negative market implications; this reduces the expected near‑term revenue runway from that program and increases execution risk. Reuters: Treatment for eye disease fails late‑stage trial
• Negative Sentiment: CEO Eric Venker sold 14,229 shares at an average $24.10 (a ~42% reduction in his holdings), a disclosure that can amplify negative sentiment after the clinical setback; insiders selling after disappointing news may concern some investors. SEC Form 4: Insider Sale

Analyst Upgrades and Downgrades

Several research firms have commented on IMVT. Truist Financial upped their price target on Immunovant from $16.00 to $22.00 and gave the company a “hold” rating in a report on Thursday, January 8th. HC Wainwright restated a “buy” rating and set a $35.00 price objective on shares of Immunovant in a research report on Tuesday, February 10th. Sanford C. Bernstein began coverage on Immunovant in a research note on Friday, March 20th. They issued a “market perform” rating and a $28.00 target price for the company. Wolfe Research raised Immunovant from a “peer perform” rating to an “outperform” rating and set a $50.00 target price for the company in a research report on Tuesday, January 6th. Finally, Guggenheim lifted their price target on shares of Immunovant from $41.00 to $44.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Six equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Immunovant presently has an average rating of “Hold” and a consensus target price of $32.00.

Immunovant Company Profile

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.